ストックスクリーナーアプリを入手
25.46
0.16%
-0.04
前日終値:
$25.50
開ける：
$25.56
24時間の取引高:
81,476
Relative Volume:
0.33
時価総額：
$1.68B
収益：
$282.04M
当期純損益:
$221.88M
株価収益率:
7.5643
EPS:
3.3658
ネットキャッシュフロー:
$-449.57M
1週間 パフォーマンス:
-1.39%
1か月 パフォーマンス:
-3.30%
6か月 パフォーマンス:
-13.05%
1年 パフォーマンス:
-20.93%
1日の値動き範囲:
$25.26
$25.56
1週間の範囲:
$25.07
$26.39
52週間の値動き範囲:
$22.36
$32.57
Galapagos Nv Adr Stock (GLPG) Company Profile
GLPG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
25.46 | 1.68B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | ダウングレード | Kepler | Hold → Reduce |
| 2024-09-09 | 開始されました | Leerink Partners | Market Perform |
| 2024-08-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-08-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | アップグレード | Jefferies | Underperform → Hold |
| 2022-11-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-19 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-08-06 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-04-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-02-19 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | 開始されました | Maxim Group | Buy |
| 2020-10-21 | ダウングレード | Goldman | Neutral → Sell |
| 2020-08-25 | ダウングレード | Jefferies | Buy → Hold |
| 2020-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-08-19 | アップグレード | Citigroup | Neutral → Buy |
| 2020-07-10 | ダウングレード | Stifel | Buy → Hold |
| 2020-03-30 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-18 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-12-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-12-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | 開始されました | BofA/Merrill | Neutral |
| 2019-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2019-07-31 | アップグレード | UBS | Neutral → Buy |
| 2019-07-29 | ダウングレード | Jefferies | Buy → Hold |
すべてを表示
Galapagos Nv Adr (GLPG) 最新ニュース
Galapagos To Spin Off Innovative Medicines Business - Forbes
Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos NV announces retirement of CEO - Seeking Alpha
Galapagos Gets First Commercial Drug With Jyseleca Approval - Yahoo Finance
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com
AIM tech shares that broke America - Interactive Investor
Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
GalapagosAll Time High - Seeking Alpha
Galapagos Nv Adr (GLPG) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):